TIANYUAN HEALTH (00557): The Stock Exchange has decided that trading in the Company's shares will be suspended.

date
06:26 23/11/2026
avatar
GMT Eight
TIANYUAN HEALTH (00557) announced that on November 20, 2026, the Company received a letter from the Stock Exchange notifying the Company that, as the Company has failed to maintain sufficient business operations and assets of substantial value to support its operations so as to warrant the continued listing of its shares (under Listing Rule 13.24), it has decided that trading in the Company's shares will be suspended under Listing Rule 6.01(3).
TIANYUAN HEALTH (00557) announced that on November 20, 2026, the Company received a letter from the Stock Exchange notifying the Company that, as the Company has failed to maintain sufficient business operations and assets of substantial value to support its operations so as to warrant the continued listing of its shares (under Rule 13.24 of the Listing Rules), it has decided that trading in the Company's shares will be suspended under Rule 6.01(3) of the Listing Rules. Under Chapter 2B of the Listing Rules, the Company is entitled to submit the Decision to the Listing Committee for review. Any review application must be served on the Secretary of the Listing Committee within seven business days from the date of the Decision (i.e., on or before December 1, 2026). Trading in the Company's shares will be suspended on December 2, 2026 (i.e., upon the expiry of seven business days from the date of the Decision, unless the Company applies for a review of the Decision). Under Rule 6.01A(1) of the Listing Rules, if trading in the shares remains suspended for 18 months, the Stock Exchange may cancel the listing status of the Company's shares. This does not affect the Stock Exchange's rights under Rules 6.01 and 6.10 of the Listing Rules to impose a specific remedial period (which may end earlier than the prescribed remedial period) or to immediately cancel the listing status of the Company's shares. The Company is currently reviewing the letter and conducting internal discussions on the matter, and will consider whether to submit an application requesting that the Decision be referred to the Listing Committee for review.